This free masterclass is a unique opportunity to get FREE trade ideas and perspectives from both a member of the Options Trading Hall of Fame and every day trader who grew his wealth from his home office.
It starts on Wednesday, Jan. 28 at 2 p.m. ETin the MTALive chatroom.
Between the Greenland situation and the WEF meeting, I was feeling decision fatigue on Friday.
As a trader, when mental power starts slowing down, you have to keep your wits.
Patience becomes key.
And one of the lotto setups I was waiting on was Carvana (CVNA).
The chart looked incredible.
It was nearing all-time highs at $485 with an A+ squeeze.
Given this momentum potential, I took out a lotto trade and 1 butterfly trade targeting $500 on Thursday.
I paid .39 for this butterfly trade on CVNA.
By the end of the trading day, it was closing at $2.13.
So I closed the first lotto for a 400% gain, but I wasn’t done yet.
Although the lotto was closed, I held on to the butterfly trade for a few reasons…
One, I thought CVNA had more room to run.
Two, given that CVNA options were super cheap the next day, I could capture that continued momentum without as much risk.
All I needed was a little push into all-time highs.
So I added to the lotto on Friday.
Then in less than 1 hour, that momentum shift came.
CVNA moved up into all-time highs, and I closed the lotto trade for a 370% winner.
All together – we captured nearly a 1000% gain on CVNA – all in less than 2 trading days.
Freaking awesome.
That’s the power of using patience and building on a lotto trade for a massive gain.
The one thing I caution traders is once you capture that massive gain – there’s a temptation to get back in on a quick dip and try to ride it for more.
Don’t do it.
I can’t tell you the number of times I’ve made a big gain on an options trade only to give it all back by thinking it’ll keep going higher.
Once I get the move into all-time highs, I close the trade and avoid trading that name for the rest of the day (usually).
Here’s what a few Daily Profits Live members had to say about the trade.
Carvana has the potential to keep running, so I’ll be looking to position via spreads in this week and next week in Daily Profits Live.
SPONSORED
Elon Musk’s Final Project REVEALED
It’s a secret project … bigger than Tesla … bigger than SpaceX … and bigger than Twitter.
You are receiving this email because you subscribed to Trade of the Day Wake-Up Watchlist. To unsubscribe from Trade of the Day Wake-Up Watchlist, click here.
Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox.
To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201
Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation.
Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.
Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.
(TLSA) Comes Backed By 7 Potential Catalysts (See Below)
Full Coverage Will Be Starting Very Shortly
Take A Close Look At (TLSA) While It’s Still Early…
January 26, 2026
First Look | See Why (TLSA) Just Jumped On To Our Early Morning Watchlist
Dear Reader,
The landscape of neurological medicine is shifting as a single biotech firm advances a delivery method that could change how we address some of the most stubborn diseases of the human brain.
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is currently at the center of this transition, utilizing a unique intranasal approach to treat neurodegenerative conditions that have long lacked effective solutions.
With a recent peer-reviewed publication and a surge in institutional support, this company is demanding the attention of anyone monitoring the future of biotechnology.
And that’s just some of the reasons why (TLSA) is topping our watchlist this morning—Monday, January 26, 2026.
Even at this early stage, (TLSA) is starting to stand out as one of the more closely followed names in neuro-immunology, thanks to a delivery approach that directly addresses the central nervous system.
And now, outside observers are beginning to put hard numbers around what that progress could mean.
Analyst Target Suggests Over 400% Upside Potential
One analyst has begun to take note of the progress at Tiziana Life Sciences, Ltd. (Nasdaq: TLSA).
Recently, Elemer Piros, PhD, an analyst withLucid Capital Markets, published a bullish rating on the company. Dr. Piros set an $8 target on (TLSA), which suggests a 406% potential upside from its recent price range of $1.58.
This valuation is largely driven by the potential of the Foralumab platform and its applicability across a potential $33B market.
The analyst community often looks forde-risking events, and the recent peer-reviewed data for SPMS is considered a major milestone. As the company moves toward Phase 2 results in both MS and Alzheimer’s, the potential for upward revisions in valuation remains high, especially if thesafety profile continues to hold up in larger patient populations.
The Tiziana Approach to Neuro-Immunology
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is a clinical-stage biotechnology company headquartered in London and New York, dedicated to developingtransformative therapies that leverage the body’s own immune system. The company’s primary focus revolves around its proprietary platform for theintranasal delivery of monoclonal antibodies.
Unlike traditional intravenous methods, thisnasal-to-brain route is designed to bypass the blood-brain barrier, potentially allowing for localized therapeutic effects in the central nervous system while minimizing systemic side effects.
The company operates in the high-stakesneuroscience market, specifically targeting Secondary Progressive Multiple Sclerosis (na-SPMS), Alzheimer’s disease, and Amyotrophic Lateral Sclerosis (ALS).
What makes (TLSA) distinctive is its lead candidate,Foralumab, which is the only entirely human anti-CD3 monoclonal antibody in clinical development.
By modulating T-cell responses and reducing neuroinflammation, (TLSA) aims to provide a new standard of care for patients who have exhausted traditional options.
Founded in 1998, the company has spent decades refining its approach toimmunotherapy. Its lean and virtual research model allows it to focus capital on high-value clinical activities rather than heavy overhead. This strategic structure has enabled TLSA to maintain a robustpipeline while advancing multiple orphan and large-market indications simultaneously.
The Scientific Foundation: Intranasal Foralumab
At the heart of Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is the scientific conviction that neuroinflammation is a primary driver of disease progression in the brain.Foralumab works by binding to the T-cell receptor complex, specifically the CD3 epsilon subunit. When administered through the nasal cavity, the therapy is designed to stimulateregulatory T cells (Tregs) in the cervical lymph nodes.
These “calming” cells then migrate to the brain, where they work to dampen the activity ofmicroglia—the immune cells of the central nervous system that, when overactive, cause tissue damage in MS and Alzheimer’s patients.
Thismechanism of action is a radical departure from traditional treatments. Most current MS therapies focus on systemic immunosuppression, which can leave patients vulnerable to infections.
In contrast, (TLSA) focuses onlocal modulation. By harnessing the body’s natural regulatory pathways, the company hopes to restorehomeostasis in the brain without compromising the rest of the immune system.
Clinical Momentum and Market Positioning
The core thesis for Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) rests on its recentclinical validation and its unique position in the neuro-immunology sector.
On January 20, 2026, the company announced thepeer-reviewed publicationof clinical study results for intranasal Foralumab, which showed signs of stabilizing disease progression and reducing microglial activation in patients with na-SPMS.
This publication in a respected medical journal provides a layer ofscientific credibility that is essential for biotechnology firms approaching late-stage trials.
Targeting Massive Unmet Needs
The market potential for (TLSA) is substantial, as the globalMultiple Sclerosis market is projected to be worth approximately $16.8B in 2026. Specifically, the non-active Secondary Progressive Multiple Sclerosis (na-SPMS) population represents asignificant segment of patients—estimated at roughly 30% to 40% of all MS cases—who currently have no FDA-approved treatments.
By positioning Foralumab as a potential first-in-class therapy for this group, (TLSA) is entering an area with minimal direct competition and high demand.
The company is also moving aggressively into Alzheimer’s disease, having already dosed the first patient in a Phase 2 trial.
With the global Alzheimer’s market projected togrow over 300% from around $7.7B in 2026 to over $33.6B by 2034, a successful inflammation-based therapy could represent a massive therapeutic class.
Unlike treatments focused strictly on amyloid plaque removal, TLSA is targeting theneuroinflammation that often persists even after plaques are cleared.
This rapid market expansion, driven by a global aging population, suggests that even a small share of the Alzheimer’s market could be transformative for a clinical-stage firm.
Strengthened Financial and Leadership Support
Operational achievements have been matched by a bolsteredbalance sheet. In January 2026, (TLSA) closed an oversubscribed $8.8M registered direct offering, following a previous announcement of an offering up to $17.6M. This capital infusion is intended to fund the continued Phase 2a clinical trial of Foralumab.
Furthermore, theExecutive Chairmanrecently increased his personal stake in the company, signaling strong internal confidence in the firm’s trajectory.
The company currently maintains a market capitalization of approximately $174M, with recent analyst notes highlighting that the current valuation may not fully reflect the potential of itsmulti-indication pipeline. With recent funding secured, (TLSA) has extended its runway to meet several high-impact data readouts expected throughout 2026.
Expert Management and Strategic Presence
Themanagement team at TLSA consists of seasoned veterans from major pharmaceutical backgrounds. Executive ChairmanGabriele Cerrone has a history of founding and scaling successful biotech ventures, including companies later acquired by major players like Bristol Myers Squibb.
This level of experience is vital for navigating the complex regulatory and commercial hurdles of theFDA approval process.
Their presence was felt during the9th Annual Neuroscience Innovation Forumheld during the J.P. Morgan Healthcare Conference week in San Francisco. This platform allowed the company to showcase itspipeline to global institutional observers and potential strategic partners. Engaging with the broaderbiotech community at such a critical venue underscores the company’s commitment to transparency and clinical progress.
Beyond MS: A Versatile Pipeline
While MS and Alzheimer’s are the leading programs, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is developing a platform, not just a single application. The company has clinical assets targetingALS, a devastating condition with few viable treatments. Preclinical data suggests that the sameTreg stimulation seen in MS could help slow the motor neuron degradation characteristic of ALS.
Additionally, the company owns rights toMilciclib (TZLS-201), an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs). Milciclib has already shownsafety and tolerability in over 300 patients across Phase 1 and 2 trials for advanced solid cancers. By maintaining a diversified portfolio that includes bothoncology and neurodegenerative programs, (TLSA) mitigates the risk inherent in single-program biotech firms.
The company’sTZLS-501 program also explores the use of anti-interleukin-6 receptor (anti-IL6R) monoclonal antibodies. This asset is being explored for its potential to treat lung inflammation, demonstrating the breadth of the company’sintellectual property portfolio. The ability to pivot this technology to various inflammatory sites makes (TLSA)a versatile player in the immunotherapy space.
7 Reasons Why (TLSA) is Topping Our Watchlist This Morning
—Monday, January 26, 2026…
1. Analyst Target: With an $8 targetfrom Lucid Capital Markets, (TLSA) is framed as having over 400% upside potential based on its recent range.
2. Chart History: Around this time last year, (TLSA) showed sharp volatility with an approximate 300% move in under 6 months, from around $0.65 to $2.60.
3. Peer Validation: A recent peer-reviewed publication of intranasal Foralumab results gives (TLSA)independent scientific support for its core approach.
4. Oversubscribed Funding: Anoversubscribed $8.8M registered direct offering in January 2026 provides (TLSA)added liquidity to pursue upcoming clinical milestones.
5. Insider Confidence: A recent increase in the Executive Chairman’s personal stake signals internal confidence at (TLSA) from someone closest to the program.
6. Clinical Momentum: Movement toward Phase 2 results in MS and Alzheimer’s keeps (TLSA) positioned around multiple 2026 data readouts tied to markets cited as roughly $16.8B for MS and about $33B for Alzheimer’s.
7. High-Profile Visibility: Participation during J.P. Morgan Healthcare Conference week in San Francisco helped place (TLSA) in front of institutional observers and potential partners.
Take A Close Look At (TLSA) While It’s Still Early…
When you put the pieces together, (TLSA) checks several boxes that serious market watchers tend to prioritize: an analyst target that suggests over 400% upside potential, a demonstrated history of sharp swings, and a peer-reviewed publication supporting its intranasal Foralumab results.
Add in fresh capital from an oversubscribed $8.8M raise, an Executive Chairman increasing his personal stake, and ongoing Phase 2 momentum in both MS and Alzheimer’s—and you can see why attention is building.
The fact that (TLSA) also showed up during J.P. Morgan Healthcare Conference week only reinforces that it’s on more radar screens than it was before.
We have all eyes on (TLSA) this morning.
Take a close look at (TLSA) while it’s still early.
Also, keep a lookout for my next update, it could be on its way to you before the bell rings.
Sincerely,
Gary Silver Managing Editor, Market Crux
MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, MC is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 01/25/2026 and ending on 01/26/2026 to publicly disseminate information about (TLSA:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Headline Media LLC has been paid twenty one thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Headline Media LLC, TD Media LLC and their member own shares of (TLSA:US).
“We’ve been consuming this ultra-processed food, which I call human pet food,” says Dr. Shawn Baker. A former orthopedic surgeon and world champion athlete, he’s the author of “The Carnivore Diet” and co-founder of the online clinic Revero.
Our mailing address is: The Epoch Times. 229 W. 28 St. Fl. 7 New York, NY 10001 | Contact Us
The Audio Room newsletter is one of the best ways to receive the most up-to-date information. Manage your email preferences here or unsubscribe from The Audio Room her
Trump’s $500 Billion Artificial Intelligence Infrastructure Initiative Could Drive These 5 Stocks Higher
Dear Reader,
It’s the end of the first calendar year of President Trump’s second term, and the results are clear. Markets are at record highs, and investors are pouring capital into the sectors most favored by his administration’s economic agenda.
At the center of this growth is Trump’s $500 billion artificial intelligence infrastructure initiative, a cornerstone policy driving major gains across banking, energy, and defense.
Our analysts have identified five companies best positioned to benefit from these developments. You’ll find them in our free report, 5 Best Stocks to Buy Under the Current Administration.
Inside, you’ll see:
A banking powerhouse expanding as deregulation deepens
An energy leader increasing production at record levels
A defense contractor capturing new federal spending
An immigration services firm gaining from border policy changes
A media company growing with the “Patriot Economy”
If you missed the early rally, this second phase of Trump’s economic resurgence could be your next opportunity.
Get your complimentary copy now before the next policy announcement moves these stocks again.
Download The 5 Best Stocks to Buy Under the Current Administration Report
By clicking ‘Download the Report’ you will subscribe to Wealth Creation Investing and will also receive a free subscription to Monument Traders Alliance
StartEngine is aiming to lead that shift. The platform has seen $1.5B invested from a community of 2.1M+,² including investments in offerings for exposure to pre-IPO companies like Databricks and Groq.³
Now StartEngine is preparing to close its own funding round after its strongest year ever, with $92M revenue YTD in 2025 and EBITDA-positive every quarter.⁴
This is a paid advertisement for StartEngine’s Regulation A+ Offering and is not a recommendation or offer to buy or sell securities. The advertiser, Strikepoint, acting on behalf of StartEngine Crowdfunding, Inc., has paid Darwin Investor Network $6,000 to distribute this advertisement across email and media channels. Neither the advertiser nor Darwin Investor Network owns, or has any agreement to receive, shares or other securities of StartEngine Crowdfunding in connection with this promotion. This compensation creates a conflict of interest, as Darwin is incentivized to promote this offering.
Darwin Investor Network is not registered or licensed as a financial advisor, broker-dealer, or investment professional. We do not provide financial, investment, or trading advice. The information contained herein is based on publicly available sources but has not been independently verified. Investors should not rely on this information without conducting their own independent due diligence.
Investing in small-cap, microcap, or early-stage companies involves significant risk, including the possible loss of your entire investment. These securities may be illiquid and subject to significant price volatility. Past performance is not indicative of future results.
The promoted company, its affiliates, or third-party shareholders may sell shares during or after this promotion, which could negatively affect the price of securities. Companies featured in investor awareness campaigns may experience substantial fluctuations in price and volume.
Offering Disclosures (Provided by StartEngine):
This Reg A+ offering is made available through StartEngine Crowdfunding, Inc. No broker-dealer or intermediary involved in offering. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information, please see the most recentOffering CircularandRisksrelated to this offering, as well as theSupplementto the Offering Circular announcing the “Termination Date.” In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
Note: This information is provided for industry context only and does not imply that StartEngine will achieve similar results, enter into comparable transactions, or secure an acquisition or partnership. Investing in early-stage companies carries risks, with no guarantee of liquidity or future returns.
2. Count determined as number of unique email addresses in StartEngine’s database as of 04-03-2025. One individual may have more than one email address. In May 2023, StartEngine acquired assets of SeedInvest, including email lists for SeedInvest’s users, investors and founders. Click here for more details. Amount invested includes $470M in funds raised previously through offerings conducted on www.seedinvest.comoutside of the StartEngine platform.
3. The underlying companies held by StartEngine Private Funds LLC, and StartEngine Private LLC (together, “StartEngine Private”) are not participating or involved in the offering. The availability of company information does not indicate that the company has endorsed, supports or otherwise participates with StartEngine Private or any of its affiliates. StartEngine Crowdfunding LLC purchases shares from current and former employees, early investors, and advisors of the companies and sells the shares to StartEngine Private for each offering. When you make an investment in a company on StartEngine Private, you are purchasing an interest in a series of StartEngine Private Funds LLC or StartEngine Private LLC, each a Delaware limited liability company (together the “Series LLCs”), which were created to hold shares of privately held companies. An investor will not directly own or hold shares of the private company but instead will own member interests in a series of the Series LLCs, which either directly or indirectly, will hold shares in the company. There may not be a one-to-one economic parity on the value of the Series LLCs interests and the underlying shares.
4. Based on our Q3 2025 Form 10-Q/A. This revenue growth has been driven by StartEngine Private, a new product line that offers funds in late stage companies. This product line has driven over $75.9 million of the $92.7 million in revenue from the first 9 months of 2025. To understand the impact on margins, see financials. Past performance may not be indicative of future performance.
We define Adjusted EBITDA as net income (loss) calculated in accordance with GAAP adjusted to exclude interest expense, interest income, income taxes, depreciation, and amortization, and stock-based compensation. We present Adjusted EBITDA because it is a key measure used by our management team to evaluate our operating performance, generate future operating plans and make strategic decisions. We believe Adjusted EBITDA provides useful information to investors regarding our operational performance and our ability to generate cash flows. Non-GAAP information should be considered as supplemental in nature and is not meant to be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, our non-GAAP financial measures may not be the same as or comparable to similar non-GAAP financial measures presented by other companies.
Please see the table on page 36 of our Q3 2025 Form 10-Q/A. This reconciles net income (loss), the most directly comparable U.S. GAAP measure, to Adjusted EBITDA for the periods presented.
5. Bonus shares in this offering are stackable. The maximum amount of bonus shares that an investor can receive is 20%. Any investor who falls into two of the three categories above will receive 20% bonus shares, as will anyone who falls into all three categories.
For example, if an investor reserved shares in StartEngine and is a Venture Club member, they will receive 20% additional shares. If that person also invests over $30,000, they will still receive the maximum of 20% bonus shares. Bonus shares may not immediately appear on your investor dashboard, but will be issued prior to the offering closing.
In order to receive perks from an investment, one must submit a single investment that meets the minimum perk requirement.
If you are investing via a self-directed IRA, you cannot receive additional perks beyond bonus shares due to tax laws.Advertising Disclosure: This email contains paid advertisements. This email is from our associates at StartEngine.
Legal Entity Information: Investing Ideas Daily is owned and operated by Darwin Investor Network, a DBA of The Darwin Agency, Inc.
Disclaimer: Nothing in this email should be considered personalized financial advice. Always conduct your own due diligence when investing. We urge you to read our full disclaimer by clicking on the terms of use link below.
Unsubscribe: You are receiving this email as part of your complimentary subscription to the Investing Ideas Daily E-Letter. If you would like to unsubscribe, you can do so by clicking on the unsubscribe link below.Darwin Investor Network 2319 N Andrews Avenue, Fort Lauderdale, FL 33311 support@investingideasdaily.com | 1-800-496-9838Investing Ideas Daily | Privacy Policy | Terms of Use Unsubscribe | View Online
Small Cap Spike: Semi Stock AEHR Up +40% in 2026 Post-Earnings
Written by Leo Miller on January 21, 2026
Key Takeaways
Aehr Test Systems has soared in the first weeks of 2026, with the catalyst being the firm’s latest earnings.
While the EV market puts pressure on sales, the company is seeing strong momentum in AI-driven demand.
Aehr’s opportunity is large, but uncertainty and a high valuation still cloud the stock’s outlook.
For shares of Aehr Test Systems (NASDAQ: AEHR), it’s hard to imagine a hotter start to 2026. As of the Jan. 20 close, the stock is already up 44% on the year.
The most recent earnings release on Jan. 8 provided mixed signals, but ultimately helped the stock shoot up 16% the next day. With revenues falling, but millions in new artificial intelligence (AI) orders coming in, what does the future hold for the semiconductor stock?
President Trump just approved two long-stalled mining projects tied to strategic U.S. minerals — including silver, which recently broke $68 after soaring 129% last year.
So why should you care?
Because silver isn’t acting like a traditional metal anymore. It’s become essential for AI, energy, and defense… and demand is climbing faster than U.S. supply can keep up. When that happens, prices don’t rise slowly — they can reprice overnight.>> See why this matters for your savings
AEHR’s Earnings: Revenues Plummet, But Booking Projections Come in Strong
On Jan. 8, Aehr reported its Q2 fiscal 2026 (FY2026) earnings. (Note that Aehr’s fiscal reporting period is ahead of the calendar period.) The results painted a mixed picture. The firm recorded revenue of $9.9 million, down 27% year-over-year (YOY) and significantly below the $11.5 million analysts had forecast.
However, Aehr’s adjusted loss per share (EPS) was significantly better than expected, coming in at a loss of 4 cents versus an estimated loss of 8 cents.
The company’s adjusted net loss was $1.3 million, compared with a net income of about $700,000 last year. Notably, the company’s effective backlog increased from $17.5 million in the prior quarter to $18.3 million.
Despite negative earnings news, Aehr’s management provided guidance that was a bright spot in the report.
Over the next two quarters combined, Aehr expects revenue of $25 million to $30 million. This compares to the $32.3 million in revenue Aehr generated in the back half of its fiscal 2025. Aehr also projects bookings of $60 million to $80 million during this period. These bookings can then translate into significant revenue during fiscal 2027.
Bookings coming through and translating into revenue in FY2027 would put Aehr solidly back in growth mode. Based on the company’s guidance, total revenue in FY2026 will be between $46 million and $51 million. The expectation that Aehr’s business will begin to recover stems from its growing presence in the artificial intelligence (AI) market.
AI-Optimism Fuels AEHR as SiC Takes a Backseat
Aehr also said on Jan. 8 that it received over $5.5 million in additional orders for its Sonoma systems. Aehr notes that these orders came from multiple “leading-edge AI companies.” Sonoma demand is accelerating—less than halfway through its fiscal Q3, the company has already received more orders than in all of fiscal Q2.
While Sonoma and AI-driven demand are key growth drivers for Aehr, it is important to understand why the company’s revenue is still declining steeply despite these drivers.
Previously, Aehr saw significant demand from the electric vehicle market. Customers used its FOX-P family of products to stress-test power chips based on silicon carbide (SiC), resulting in strong revenue growth from 2021 to 2023.
SiC-based devices provide substantial benefits over EV power chip technologies that currently dominate the market. This includes the ability to extend EV range by 5% to 10%and cut charging time in half. Aehr believesthat most, if not all, EV companies will move toward SiC-based technology in the future.
However, slowing growth in the EV markethas hurt SiC demand more recently. As SiC demand was previously the company’s largest revenue driver, and AI-driven revenue is still small in comparison, Aehr’s overall sales are dropping.
Pursuant to this, Aehr says that the bulk of its expected bookings are AI-driven, while attributing “not very much at all” of them to SiC. Furthermore, Aehr believes that initial AI customers will expand their orders meaningfully during 2027 and 2028. The company estimates that the AI test-and-burn-in market is between $8 billion and $10 billion today and could reach $15 billion. Clearly, Aehr’s revenues and potential bookings are very small in comparison, providing a large growth opportunity.
Gold Above $5,000 per Ounce in 2026! Here’s How to Play It…
With so many strange events happening across the economy (consumer confidence plummeting, credit-card delinquencies soaring, and more), it’s no wonder the richest investors are loading up on gold. But what you might not realize is that there’s a much better way to profit from rising gold prices – WITHOUT ever touching an ETF, mining stock, or even bullion.Get the full details here.
AEHR: AI-Upside Is Real for This Unproven Player
Aehr’s outlook shifted in a significantly positive direction after its latest financial updates. Still, based on FY2027 estimates, the stock trades at more than 12 times its forward sales. That is not a cheap figure.
However, further momentum in the company’s AI business over the next several quarters could lead to a significant increase in sales estimates. But there is no guarantee that this will materialize, or that Aehr will meet expectations that are already set. Aehr continues to be a stock with strong upside potential, but also prevalent risks.
Investors enter a packed earnings week with markets holding near key technical levels. While the S&P 500 remains rangebound, the Russell 2000 has emerged as a leader—breaking to new highs in recent sessions and setting the tone for small-cap outperformance. The pattern suggests a shift in risk appetite, but the broader trend remains cautious ahead of key catalysts.
Steel Dynamics kicked off the week with Monday morning’s earnings report, offering early insight into the industrial economy. It’s just the beginning—other major reports from UnitedHealth, UPS, Whirlpool, and Tractor Supply are still to come. These names will provide updates across healthcare, logistics, manufacturing, and retail, helping investors gauge the strength and breadth of the economic recovery.
On the macro front, all eyes are on the Fed. Wednesday’s FOMC meeting won’t likely bring a rate cut, but investors will be watching closely for any change in tone. With inflation still above target and labor markets holding steady, the Fed has reason to stay cautious. Last week’s mixed data—solid jobless claims, stable GDP trends, and modest inflation readings—offered little urgency for a policy shift.
Markets aren’t in crisis mode, but momentum is fragile. Many companies are guiding cautiously for Q1, though full-year outlooks remain largely intact. With earnings season accelerating and the Fed set to weigh in, this week could shape sentiment well into February.
Healthcare stocks rallied in 2025, breaking a two-year slump as investors chased steadier rates, better valuations, and improving earnings. The problem: mid-single-digit gains still lagged tech, leaving the sector feeling like a missed opportunity. For investors still hunting for healthcare growt…READ THE FULL STORY
Gold and silver prices are climbing. Global tensions are back in the headlines. Markets are reacting fast. In moments like this, experienced investors don’t trade more, they simplify. A new report breaks down 10 U.S. stocks you can buy and hold with confidence, businesses positioned to benefit from AI, cloud computing, healthcare, and long-term demand. This isn’t a hype list. It’s a long-term playbook designed for uncertain markets, including how to think about allocation when volatility spikes.ACCESS THE FREE 10-STOCK REPORT BEFORE AVAILABILITY CLOSES.
Procter & Gamble (NYSE: PG) confirmed a bottom in early 2026, with its stock price set to advance significantly over the coming years. Trading at long-term lows, the market had priced in the worst-case scenario: tepid growth. However, tepid growth is enough to sustain the company’s fi…READ THE FULL STORY
For companies that have recently returned to the public markets, the first major acquisition is a defining moment. It signals to investors exactly how management intends to use its capital to generate growth. Smithfield Foods (NASDAQ: SFD), which completed its Initial Public Offering (IPO) in Ja…READ THE FULL STORY
Tired of chasing the market every week? Our new free report reveals 10 U.S. stocks you can confidently buy now and hold long term — handpicked by a veteran investor with over 20 years of experience and backed by deep research into megatrends like AI, EVs, and cloud tech.CLICK HERE TO GET THE 10 STOCKS TO BUY AND HOLD — FREE FOR A LIMITED TIME
Many of the themes that pushed stocks higher in 2025 are back in focus to begin 2026. One of those is the bull market for precious metals. Many eyes are on silver, which has hit an all-time high. But investors shouldn’t sleep on gold, which shook off early-year weakness and reached a new all…READ THE FULL STORY
Abbott Laboratories’ (NYSE: ABT) January 2026 price pullback is making its stock look attractively valued. The move, driven more by market angst and fear than by any real weaknesses, seems to be a knee-jerk overreaction that has launched the stock back into the buy zone. The zone in question al…READ THE FULL STORY
Markets have been volatile lately, but dependable income opportunities still exist for investors who know where to look. We’re reviewing a small group of high-yield dividend stocks that continue to generate strong cash flow despite shifting conditions. Our latest guide outlines three companies operating in energy, consumer staples, and consumer finance, each producing billions in free cash flow and offering yields above typical market averages. These are established, cash-producing businesses built to reward shareholders through consistent payouts, not speculation. If steady income matters in today’s market, this breakdown is worth a closer look.ACCESS THE FREE DIVIDEND INCOME GUIDE AND REVIEW ALL THREE STOCKS TODAY
While the Magnificent Seven and massive technology conglomerates often dominate financial headlines, a quieter but equally significant shift is occurring in the small-cap sector. January 2026 has emerged as a critical month for a few specific companies valued under $2 billion. These firms are tran…READ THE FULL STORY
Shares of tech stock Atlassian Corp (NASDAQ: TEAM) are trading right around $130, after starting the year above $160. Considering the S&P 500 index is up more than 1% over that same timeframe, it’s been a pretty brutal start to the year for investors. It will perhaps, unfortunately, not hav…READ THE FULL STORY
The first month of the new year has put stocks on a roller coaster that reminds investors that volatility isn’t going away anytime soon. But gold and silver continue ignoring the noise and moving higher. In fact, at the close of markets on Jan. 22, the spot price of silver cracked the $95 ma…READ THE FULL STORY
If you’re searching for something on the internet and your web browser slows to a crawl, what’s the first thing you do? You hit the refresh button in hopes of speeding up the data and loading the website faster. It’s a similar concept to the one analysts at Piper Sandler believe …READ THE FULL STORY
Over the past year, airline stocks have trailed the broad market as the industry deals with elevated operating costs, economic uncertainty tamping down demand for flights, and pilot labor shortages. Complicating matters, the record-long government shutdown in the fall of 2025 adversely affected …READ THE FULL STORY
Gibraltar Industries, Inc. manufactures and provides products and services for the renewable energy, residential, agtech, and infrastructure markets in the United States and internationally. It operates through four segments: Renewables, Residential, Agtech, and Infrastructure. The Renewables segment designs, engineers, manufactures, and installs solar racking and electrical balance of systems for commercial and distributed generation scale solar installations. The Residential segment offers roo…VIEW TODAY’S STOCK PICK
The Early Bird is a daily email newsletter powered by MarketBeat that covers the top stories that will impact the stock market each day. Read your copy every morning at 7:00 AM Eastern so that you can “catch the worm” when the market opens.
🚨 Traders! 🚨 $VWAV is front and center to start this glorious week. This thing was trading around $15 not that long ago — is this the bounce setup we’ve been waiting on?
The pull back is in place…
And remember… last week we saw a stock rip from $0.40 → $0.90.
Momentum can hit fast! SO be ready for ANYTHING!!!
(NASDAQ:VWAV) LFG!!!
Full report below compensation in disclaimer.
VWAV: The Defense-AI Opportunity Most Investors Are Missing as Global Military Spending Accelerates into a New Era.
VisionWave Holdings (NASDAQ: V WAV) Could Emerge as One of the Most Important Small-Cap Defense-AI Stories of 2026.
Greetings All,
Defense Spending Is Surging—and the Nature of Warfare Is Changing!
In today’s geopolitical environment, defense is no longer a discretionary budget item—it is a strategic imperative. Global military spending has surged to $2.7 trillion annually, and much of that capital is being funneled toward artificial intelligence, autonomy, and real-time decision systems.
As nations modernize their forces and prepare for a new generation of threats, a small group of companies is positioning itself at the heart of this transformation.
One of the most under-the-radar names in that group is VisionWave Holdings (NASDAQ: VWAV), a defense-AI company that stands out not for hype, but for architecture, validation, and real-world deployment potential.
From Private Innovator to Nasdaq-Listed Defense Platform
VisionWave’s 2025 Nasdaq debut, completed through its merger with Bannix Acquisition Corp., marked a pivotal shift in the company’s trajectory. Moving to the public markets unlocked institutional access, expanded financing options, and eligibility for multi-year government contracts—critical prerequisites in defense procurement.
Unlike many speculative startups, VWAV now operates as a public, deployment-ready defense technology company with an expanding global footprint that includes the U.S., Israel, the UAE, India, and Europe.
Evolved Intelligence™: AI Designed for the Battlefield, Not the Cloud
At the core of VisionWave’sdifferentiation is its proprietary Evolved Intelligence™ (EI) platform. Unlike cloud-dependent AI systems, EI is purpose-built to function at the edge—where connectivity is unreliable and latency can be fatal.
The platform fuses AI reasoning, sensor fusion, RF intelligence, and deterministic autonomy into a single architecture capable of perceiving, deciding, and acting independently. This design allows autonomous drones, ground systems, and sensing platforms to operate effectively in real-world combat environments, where traditional GPU-heavy, cloud-reliant AI models often fail.
Technology That Works Where Others Can’t
Third-party validation is rare and valuable in defense technology, and VisionWave has secured it.
The November 2025 Vanderbilt Report highlighted VWAV’s patented RF-AI co-design and its ability to operate under extreme SWaP (Size, Weight, Power) constraints.
While conventional AI systems drain power and depend on persistent connectivity, VisionWave’s lightweight, heuristic-first architecture conserves energy and extends mission duration.
The report concluded that VWAV’s approach is extraordinarily difficult to replicate, even for well-funded competitors—an important signal for long-term defensibility!
Capital Strength and Real-World Defense Pilots
VisionWave’s growth strategy is supported by a $50 million equity line and immediate strategic funding, allowing the company to scale without relying on high-burn venture capital models.
This capital is being deployed to accelerate pilots, system integrations, and international expansion. Importantly, VWAV’s technology has already been proven in Tier-1 defense pilots, including live-fire testing in the UAE and active evaluations with U.S. defense stakeholders.
These are not theoretical demonstrations—they are real-world validations that can evolve into long-term revenue pipelines.
Leadership That Opens Doors in Global Defense Markets
Defense contracts are built on trust as much as innovation. VisionWave has strengthened its credibility with the addition of Admiral (Ret.) Eli Marom and Ambassador (Ret.) Ned L. Siegel to its advisory board.
Their command-level military experience and diplomatic expertise enhance VWAV’s ability to navigate procurement processes and convert pilots into multi-year production contracts. This is particularly relevant as the global defense radar market alone is projected to nearly double to $24.1 billion by 2034.
Multi-Domain Expansion Across Air, Land, and Infrastructure
VisionWave is not limiting itself to a single battlefield domain. The acquisition of Solar Drone adds autonomous aerial capabilities for defense and critical energy infrastructure, while upcoming Varan UGV field testing in Europe marksVWAV’s expansion into next-generation ground warfare.
Combined with its RF imaging, super-resolution radar, and AI sensing stack, VisionWave is building a full-spectrum autonomy platform spanning air, land, and infrastructure applications—aligned with how modern militaries are evolving.
Acquisition of QuantumSpeed: A Game-Changer for Real-Time Defense Computing
VisionWave strategically acquired QuantumSpeed™, a cutting-edge computational acceleration engine currently in proof-of-concept and system architecture development, to address one of the most acute challenges in modern defense systems: collapsing decision latency.
Unlike traditional approaches that rely on brute-force hardware upgrades, QuantumSpeed restructures computation through a Hybrid Successive Approximation framework that prioritizes mission-critical calculations first—enabling faster, real-time outcomes where speed can mean operational success or failure.
The acquisition was unanimously approved by VisionWave’s board following an independent valuation by BDO Consulting Group that placed the intellectual property’s worth at approximately $99.6 million, reflecting its potential strategic value.
By integrating QuantumSpeed into its technology portfolio and newly formed joint venture platform, VWAV is positioning itself to accelerate the development and integration of advanced computational capabilities across defense, autonomous systems, and other latency-sensitive applications—potentially transforming how AI-driven defense architectures perform in contested environments.
The Bottom Line
VisionWave Holdings is no longer just an emerging defense-AI concept. It is a validated, patented, and increasingly institutionalized platform company aligned with the future of autonomous warfare and real-time intelligence.
With independent technology validation, proven defense pilots, elite advisory leadership, expanding international pipelines, and capital to scale, VWAV appears positioned for a potential inflection point as programs move from testing to adoption in 2026 and beyond.
VWAV stands out as a small-cap defense-AI opportunity that many have yet to fully appreciate.
Disclaimer
We are engaged in the business of advertising and promoting companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Neither the owner of Huge Alerts nor any of its members, officers, directors, contractors or employees are licensed broker-dealers, account representatives, market makers, investment bankers, investment advisers, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed on Huge Alerts. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. Huge Alerts makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Some of the content on this website contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which may be beyond a company’s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. It is hereby noted that forward-looking statements contained herein may include everything other than historical information, involve risk and uncertainties that may affect a company’s actual results of operation. A company’s actual performance could greatly differ from those described in any forward-looking statements or announcements mentioned on this website or the websites contained within. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company’s products; the company’s ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, a company’s past performance does not guarantee future results. Generally, the information regarding a company profiled or discussed on this website is provided from public sources hugealerts.com makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained through our website or in communications originating from our website. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and Huge Alerts has no obligation to update any of the information provided. Huge Alerts, its owners, officers, directors, contractors and employees are not responsible for errors and omissions. From time to time certain content on this website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap or penny stock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled on this website may not have approved certain or any statements within the website. Huge Alerts encourages viewers to supplement the information obtained from this website with independent research and other professional advice. The content on this website is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Third Party Web Sites and Other Information This website may provide hyperlinks to third party websites or access to third party content.Huge Alerts, its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does Huge Alerts control, endorse, or guarantee any content found in such sites. Huge Alerts does not control, endorse, or guarantee content found in such sites. By accessing, viewing, or using the website or communications originating from the website, you agree that Huge Alerts, its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that Huge Alerts, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. Huge Alerts uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the United States Securities and Exchange Commission (SEC). The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or the Financial Industry Regulatory Authority (FINRA) at: www.finra.org. In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/Investors/index.htm.
Income Disclaimer
Testimonials and examples used here are exceptional results which may not apply to the average purchaser. They are not intended to represent or guarantee that anyone will achieve the same or similar results through our service. The use of our information should be based on your own due diligence, and you agree that our company is not liable for any success or failure of your business that is directly or indirectly related to the use of our information. As with any business, your results may vary, and will be based on your individual capacity, business experience and expertise. There are no guarantees concerning the level of success you may experience. Income statements made by our customers are only estimates of what they have earned; there is no guarantee that you will make these levels of income. When using our information you accept the risk that these earnings and income statements differ by individual. There is no assurance that examples of past earnings can be duplicated in the future. There are unknown risks in business and on the internet that we cannot anticipate which can reduce results. We therefore cannot guarantee your future results or success, and are not responsible for your actions.
Huge Alerts has been retained by Interactive offers to perform promotional and advertising services for a limited time with respect to the company we are profiling or discussing on this website and in exchange for such services has received cash compensation from interactive offers . Questions regarding this website may be sent to editor@hugealerts.com
Huge Alerts has been compensated by interactive offers for the total sum of $30,000.00 This agreement is for the marketing of Vision Wave Holdings (NASDAQ:VWAV) which services include the issuance of this release and other opinions that we release concerning of Vision Wave Holdings (NASDAQ:VWAV) . Huge Alerts has not investigated the background of interactive offers the hiring party, orVision Wave Holdings (NASDAQ:VWAV) Anyone viewing this newsletter should assume interactive offers or affiliates of interactive offers own shares of Vision Wave Holdings (NASDAQ:VWAV) which they plan to liquidate, and further understand that the liquidation of those shares may or may not negatively impact the share price. Huge Alerts has received this amount as a production budget for advertising efforts and will retain amounts over and above the cost of production, copywriting services, mailing and other distribution expenses as a fee for our services. As such, our opinion is neither unbiased nor independent, and you should consider that when evaluating our statements regarding Vision Wave Holdings (NASDAQ:VWAV)
Below please find a special message from one of our sponsors, De-Dollarize News.From time to time we find special opportunities we believe you as a valued customer may want to see. Please note that the following message reflects the opinions and representations of our sponsor alone, and not necessarily the opinion or editorial positions of Eagle Financial Publications or Salem Media.
The Digital Dollar Reset is no longer a conspiracy theory. It is already alive inside the banking system – and February 12 may mark the beginning of the lock-in phase.
Under the GENIUS Act, signed into law by President Trump in 2025, “stable coins” were authorized as the bridge between traditional dollars and fully programmable digital currency.
This rollout isn’t happening all at once. It’s happening quietly. In phases. With compliance baked in – making your cash flow programmable, trackable, and controllable.
Stable coins are not money. They are PERMISSION.
And permission can be REVOKED.
If you operate outside approved rules, limits, or behavior, access can be restricted or shut off – instantly.
Here’s what you’re seeing right now, whether you realize it or not:
JPMorgan is increasingly overlapping with national security priorities, including reported involvement in domestic metals processing tied to Department of Defense interests. When banking and national security merge, control always follows.
The U.S. Treasury has suspended sales of silver numismatic products. Not delayed. Suspended. Replacement costs exceeded published valuations – a signal of a system collapse.
At the same time:
Compliance is being hard-wired directly into JPMorgan’s banking structure
Internal regulators have been replaced with AI compliance systems
AI now judges transactions – not people
This is how transitions happen.
Not with announcements. With restrictions.
The dollar system you know is being re-scaffolded.
To ensure future delivery of Eagle Financial Publication’s emails please add the domain @mail.eaglefinancialpublications.com to your address book or contact list.
This email was sent to pahovis@aol.com because you are subscribed to the Carefully Selected Financial Offers from Third Parties List. To unsubscribe please click here. To stop receiving emails simply click here. View this email in your web browser.
If $68 billion were being handed out tomorrow, you’d expect to hear about it everywhere.
But according to Brad Thomas — a former advisor to President Trump — the media and Wall Street don’t want you to know about the up to $68 billion up for grabs.
In other words, that’s $8 million being paid out EVERY hour.
And these payouts were just reinforced by a mandate signed into law by President Trump.
This is money that must be paid out by Federal law every single year — no matter what happens in the market.
Steven Longenecker Editorial Director, Wide Moat Research
**The investment results described in this testimonial are not typical. Investing in securities carries a high degree of risk; you may lose some or all of the investment.
Monday’s Bonus Content
Is Abbott’s January Pullback a Good Time to Buy?
By Thomas Hughes. Article Published: 1/24/2026.
In Brief
Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories’ (NYSE: ABT) January 2026 price pullback makes the stock look attractively valued. The move—driven more by market angst than by any clear company weakness—appears to be a knee-jerk overreaction that has returned the shares to a buy zone.
Amazon has quietly poured $144 million into a secretive AI chip company, and committed to buying a staggering $650 million of their product. Why? Because this obscure startup holds the key to unleashing the full potential of Nvidia’s revolutionary Blackwell chip.Discover the company at the heart of the AI arms race.
The zone in question aligns with market action from 2022–2024, when Abbott was recovering from its post-COVID-19 revenue contraction and institutions were actively accumulating the stock.
Abbott Laboratories Growth Accelerates
The most that can be said against Abbott’s Q4 results and guidance is that a few metrics missed market expectations. Still, revenue of $11.46 billion was up 4.5% year over year, margins improved, and adjusted earnings accelerated.
Revenue growth lagged consensus by several hundred basis points, but stronger margins offset much of that, with adjusted earnings per share (EPS) rising about 12% and coming in slightly above consensus.
Segment results underscore the strength of Abbott’s diversified healthcare portfolio.
Nutrition and Diagnostic saw declines, led by a nearly 9% drop in Nutrition, but those weaknesses were offset by solid gains in Established Pharmaceuticals and Med Tech.
Established Pharmaceuticals grew roughly 9%, helped by generics and emerging-market strength, while Med Tech expanded about 12.3%, with broad-based strength across its subsegments.
Margin improvement was a positive takeaway, even if some measures fell short of certain analyst forecasts. A favorable product mix, strength in Med Tech, lower COVID-19-related sales and ongoing operational improvements supported margins, and management expects continued progress.
Looking ahead, the company projects roughly 10% earnings growth in 2026, outpacing revenue growth and supporting its capital-return plans.
Abbott’s capital returns are central to the investment case. As a Dividend King, Abbott has raised its payout annually for more than 50 years and appears positioned to continue doing so. After the pullback the stock yields about 2.5%, and the payout ratio is under 50% of consensus earnings, leaving room for share buybacks—an important offset to the dilutive effects of share-based compensation—and other shareholder returns (see analysis).
Analysts Point to Robust Rebound in Abbott Laboratories Stock
Some analysts noted the revenue miss, but there were no major rating cuts or price-target reductions the morning of the release. The prevailing view remains that this is a fundamentally healthy company that can continue returning capital while reinvesting in growth.
The MarketBeat-consensus share price target implies potential upside of as much as 30%, which could push the stock to new all-time highs, while even the low-end targets imply modest upside from current levels.
Key catalysts include an expanding Med Tech portfolio, AI integration across operations and products, margin expansion and strategic acquisitions.
The proposed acquisition of Exact Sciences is one example of how Abbott can broaden its revenue and profit streams and strengthen its product pipeline.
Abbott’s share decline has been steep and could deepen, but institutional investors accumulated shares throughout 2025 and may act as buyers now that prices are discounted.
Early technical support appears in the $105–$110 range, though it is not yet confirmed. The downside risk is that ABT could slide further to the lower end of the target buy zone—potentially toward the $95 area—before staging a sustained rebound.
Thank you for subscribing to DividendStocks.com’s daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.
This message is a sponsored email from Wide Moat Research, a third-party advertiser of DividendStocks.com and MarketBeat.
This ad is sent on behalf of Wide Moat Research, 1125 N Charles St, Baltimore, MD 21201. If you would like to optout from receiving offers from Wide Moat Research please click here.
If you need assistance with your account, don’t hesitate to email our U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
RJ Hamster 